Abstract
A series of linear and macrocyclic 2,6-disubstituted pyridine derivatives 1–7 were previously prepared and evaluated as analgesic and anticonvulsant agents. Herein these derivatives were screened as anti pancreatic cancer, anti-GIT cancer and mTOR inhibitor activities. The tested compounds were found to have in vivo and in vitro potent anti-pancreatic cancer and anti-GIT cancer activities. The mechanism of action of these compounds was evaluated as mTOR inhibitors.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Computational and Theoretical Nanoscience
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
